

# Our Business Strategy Healthcare Business (HCB)

Jan 30, 2018 OMRON Corporation

# Positioning of HCB

Positioned as a key domain alongside FA, even within the 4 focus domains





# **Social Issues Within Healthcare**

Social changes in developed and developing countries have led to new challenges in healthcare, driving severe increases in medical expenditures

Social change



Middle class expanding in both developed and developing countries



Population aging in developed countries

New challenges



Increase in lifestyle diseases



Widening gap between life expectancy and healthy life expectancy

Social issues




**Rising medical expenditures** 

### **Healthcare: 3 Focus Fields**

Aim to resolve social challenges through personalized medical solutions in the 3 therapeutic areas with sufficient global market scale and where OMRON can fully leverage its strengths


Cardiovascular Disease	Respiratory Disease	Pain Management
Cerebral and cardiovascular <sub>*1</sub> event patients	Global respiratory disease patients *2	Chronic pain patients in Japan and US
17.5 Million	440 Million	73 <sub>Million</sub>
Medical expenses for *4 cardiovascular disease	Medical expenses for respiratory diseases in Japan, US, and Europe	Analgesic market *6 in Japan and US
¥120 Trillion	¥19 Trillion	¥2.4 Trillion

\*1 WHO report \*2 International Respiratory Societies report \*3 Pain in Japan (Japan), National Health Interview (US) \*4 Estimate based on World Bank and OECD data \*5 Estimate based on published data by Ministry of Health and Welfare, European Respiratory Society, and Creative Biotech Inc. survey \*6 World Analgesic Market Research 2013





# Reinforcement of 3 Core Categories




\* World market share for blood pressure monitor and nebulizer; Japan and US market share for low frequency therapy equipment

\* Amount-based share



## **BPM Market Expected to Grow**

Global hypertension population continues to rise, expected to hit 1.5 billion by 2025. Implied growth potential for the BPM market very strong.



# **OMRON's Strengths**

The medical device business requires the ability to meet rigorous standards. OMRON has 3 key strengths, as a result of a 40 year-plus track record in the BPM business.

- 1. Significant regulatory expertise, ability to secure approvals (barrier to entry for others)
- 2. Well trusted by medical practitioners based on high degree of performance accuracy

# 3. Established channel network

Q1-Q3 Results

**HCB Strategy** 


# Strength 1. Regulatory Expertise (Barrier to Entry)

OMRON products sold in 117 countries, 90 of which have a product approval process. OMRON has met the safety and efficacy requirements of regulators in each country.



# **Strength 2. Trusted by Medical Practitioners**

Many papers have been written assessing the accuracy of OMRON BPMs. OMRON has the highest number of recommendations from dabl, a thirdparty resource used by doctors in evaluating BPMs.





#### Q1-Q3 Results

#### **HCB Strategy**


# **Strength 2. Trusted by Medical Practitioners**


OMRON BPMs widely used in large-scale clinical trials on a global basis, starting with the Ohasama Longitudinal Study, which is considered to be the basis for WHO's home blood pressure measurement standards






Copyright: 2018 OMRON Corporation. All Rights Reserved.






# Zero Cerebral and Cardiovascular Events





# Challenges in Treating Hypertension (Japan)


Leading cause of cerebral and cardiac events. Only 13% of patients successfully lower blood pressure. Better outcomes require changes to patient behavior and personalized diagnosis and treatment.



**HCB Strategy** 

# **HCB Targets Innovation in Hypertension Treatment**

Innovative devices make it possible to capture a wide array of vital signs. Analytics can then be applied to create innovative diagnostic and therapeutic services for the treatment of hypertension. This can contribute to Zero Events.



Q1-Q3 Results

**HCB Strategy** 

# First Steps for New Hypertension Treatment (with AliveCor)

Achieve Zero Events with new devices that capture a wider variety of vital sign and behavioral data to enhance diagnosis and provide more sophisticated treatment

## **AliveCor's Strengths**

 Mobile cardiograph unit (FDA-cleared)
to detect atrial fibrillation




 Remote monitoring platform for cardiologists and patients



#### **OMRON's Strengths** Development capability Integrated a New tubeless cuff-type Device **BPM** (Launched Mar. 2017) Example of a New Device Wearable BPM (In development for US launch in 2018) Algorithm - Diagnostic algorithm New - Optimal dosing algorithm Service

# Collaboration





**Full-year Forecasts** 

01-03 Results

21

**HCB Strategy** 

